Short Interest in Apollomics, Inc. (NASDAQ:APLM) Declines By 58.1%

Apollomics, Inc. (NASDAQ:APLM) was the target of a significant decline in short interest during the month of March. As of March 15th, there was short interest totalling 2,600 shares, a decline of 58.1% from the February 28th total of 6,200 shares. Approximately 0.3% of the company’s stock are sold short. Based on an average daily trading volume, of 17,100 shares, the short-interest ratio is presently 0.2 days.

Apollomics Trading Up 2.9 %

NASDAQ:APLM opened at $8.40 on Friday. Apollomics has a 52 week low of $6.20 and a 52 week high of $75.00. The company’s 50 day moving average price is $7.99 and its 200-day moving average price is $10.42.

Apollomics Company Profile

Apollomics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company’s products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain.